|Bid||61.33 x 800|
|Ask||70.91 x 1100|
|Day's Range||60.64 - 61.60|
|52 Week Range||57.54 - 75.50|
|Beta (5Y Monthly)||0.11|
|PE Ratio (TTM)||39.48|
|Forward Dividend & Yield||0.34 (0.53%)|
|Ex-Dividend Date||Jul 08, 2021|
|1y Target Est||N/A|
RDY earnings call for the period ending June 30, 2021.
Dr. Reddy's (RDY) earnings decline while sales grow year over year in first-quarter fiscal 2022.
Journey Medical Corporation, a partner company of Fortress Biotech Inc (NASDAQ: FBIO), has entered into a collaborative development and commercialization agreement with Dr. Reddy's Laboratories Ltd (NYSE: RDY) for the DFD-29 (Minocycline Modified Release Capsules 40 mg) for the treatment of rosacea. Journey Medical has acquired global commercialization rights, including the U.S. and Europe, except that Dr. Reddy's has retained certain rights to the program in select markets, including Brazil, Ru